Syntone Ventures News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Outlook Therapeutics (OTLK) Receives FDA Agreement Under SPA for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172M
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Outlook Therapeutics (OTLK) Receives FDA Agreement Under SP) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Outlook stock rallies on private placement, FDA study agreement (NASDAQ:OTLK)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Outlook Therapeutics Announces Closing of $35.0 Million Bought Deal
Outlook Therapeutics, Inc.February 2, 2021 GMT
MONMOUTH JUNCTION, N.J., Feb. 02, 2021 (GLOBE NEWSWIRE) Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced the closing of its previously announced underwritten public offering of 35,000,000 shares of common stock of the Company at a price to the public of $1.00 per share. As previously announced, the company has granted the underwriter a 30-day option to purchase up to 5,250,000 additional shares of its common stock at the public offering price, less underwriting discounts and commissions.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Outlook Therapeutics Increases Previously Announced Bought Deal Offering of Common Stock to .
Outlook Therapeutics, Inc.January 29, 2021 GMT
MONMOUTH JUNCTION, N.J., Jan. 28, 2021 (GLOBE NEWSWIRE) Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 35,000,000 shares of common stock of Outlook Therapeutics, at a price to the public of $1.00 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about February 2, 2021, subject to satisfaction of customary closing conditions.